Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide

Abstract

The present invention provides a method and composition for the treatment of Female Sexual Arousal Disorder. Calcitonin gene-related peptide, a naturally occurring substance in the human body, is chemically conjugated to a hydrophobic agent thereby increasing its permeability across the skin membrane. When locally applied to female genitalia localized blood flow is promoted thus resulting in increased sexual arousal.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The present invention relates to compositions and methods for the local administration of a therapeutic preparation for treating female sexual arousal dysfunction, and more particularly, to a preparation comprising calcitonin gene-related peptide conjugated to a hydrophobic agent and methods of use for promoting blood flow to the genital region, specifically the clitoris of a female patient. [0003] 2. Description of the State of Art [0004] According to the Journal of the American Medical Association, more than 43% of American women (about 40 million) experience some form of sexual disorder. Other reports state that 70% of post-menopausal and 25% of pre-menopausal women experience sexual dysfunction. Any woman can experience Female Sexual Dysfunction at some point in her life. Physicians and other healthcare providers recognize Female Sexual Dysfunction as a medical condition. It includes a variety of disorders that ...

AI Technical Summary

Problems solved by technology

If a woman's sexual concerns are recurring in nature and cause her personal distress, she may indeed have female sexual dysfunction.

Reduced sexual arousal may result in discomfort or even pain due to insufficient vaginal lubrication and / or a lack of physical preparation of the genitalia for sexual activity.

Pelvic nerve stimulation results in clitoral smooth muscle relaxation in an increase in clitoral cavernosal artery inflow and an increase in clitoral intracavernous pressure, which lead to tumescence and extrusion of the glans clitoris.

Reduced levels of estrogen during and after menopause also contributes to arousal difficulties as well.

Reduced clitoral arterial flow may lead to fibrosis of the clitoral cavernosa and reduced clitoral physiological function.

Certain medication can also interfere with arousal.

Antidepressants, antihypertensives, and antihistamine medications are commonly associated with adverse sexual side effects.

The direct physiological effects of these drugs interfere with the processes involved in sexual excitement.

Because most of these studies are fairly recent (or ongoing), there is not yet an FDA-approved medication for female sexual arousal disorder.

Studies of sexual dysfunction in couples have revealed that more females than males may experience arousal or orgasmic problems.

Because the prior art has focused primarily on erectile insufficiency in males and other male-related problems, there have been relatively few attempts to effectively determine and treat causes of female sexual dysfunction, for example by monitoring or measuring the above-referenced physiological changes that the female under goes during sexual arousal.